Treatment with Recombinant Human Erythropoietin in Patients with Aluminum Overload and Hyperparathyroidism

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In a European multicenter trial the weekly rates of increase in hematocrit and reticulocyte values were investigated in hemodialyzed patients with transfusion-dependent anemia treated with recombinant human erythropoietin (rHuEPO). Within a few months of therapy, the number of transfusion-dependent patients decreased to less than 5 % of the group. Patients with aluminum overload indicated by elevated basal serum levels or elevated levels after a desferrioxamine challenge showed a significantly reduced response to rHuEPO, whereas in patients with elevated levels of parathyroid hormone a normal response to rHuEPO was found.

Related collections

Author and article information

Journal

Journal ID (publisher-id): BPU

Journal ID (nlm-ta): Blood Purif

Journal ID (doi): 10.1159/issn.0253-5068

Title: Blood Purification

Publisher: S. Karger AG

ISBN: 978-3-8055-5344-5

ISBN: 978-3-318-01647-5

ISSN (Print): 0253-5068

ISSN (Electronic): 1421-9735

Publication date Subscription-year: 1990

Publication date (Print): 1990

Publication date (Electronic): 29 October 2008

Volume: 8

Issue: 5

Pages: 279-284

Affiliations

^aII Medical Clinic, St. Markus Hospital, Frankfurt; ^bClinical Research, Boehringer-Mannheim, Mannheim; ^cRIA Laboratory, Heidelberg; ^dFraunhofer Institute, Stuttgart, FRG

Article

Publisher ID: 169979 Other ID: Blood Purif 1990;8:279–284

DOI: 10.1159/000169979

PubMed ID: 2091687

SO-VID: 2c68993f-427a-4a46-9a9d-1da7a3465c8d

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

Submit here before September 30, 2024

Treatment with Recombinant Human Erythropoietin in Patients with Aluminum Overload and Hyperparathyroidism

Read this article at

Abstract

Related collections

Karger: Nephrology

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 627